Lupus Therapeutic Market, by Disease Type (Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus, Drug-Induced Lupus Erythematosus, and Neonatal Lupus), by Treatment Type (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Biologics, Antimalarial

Lupus Therapeutic Market, by Disease Type (Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus, Drug-Induced Lupus Erythematosus, and Neonatal Lupus), by Treatment Type (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Biologics, Antimalarial Drugs, Corticosteroids, and Others {Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others}), by Route of Administration (Oral, Subcutaneous, Intravenous, and Others {Intramuscular, Intradermal, among others}, by End User (Hospitals & Clinics, Diagnostic Laboratories, and Others {Homecare, Specialty Centre, among others}), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Lupus is an autoimmune disorder wherein the immune system of the body attacks body’s own healthy tissues and organs, resulting in swelling, tissue damage, and pain. The inflammation caused by lupus can affect the joints, kidneys, brain, blood cells, skin, heart, and lungs. The exact cause of lupus is unknown, however, certain risk factors are associated with lupus. These risk factors include hormones, genetics, smoking, viral infection, and others. Some of the common symptoms related to lupus include fatigue, muscle and joint pain, fever, mouth ulcers, headaches, arthritis, malar rash, unusual hair loss, and others. Diagnosis of lupus is difficult as its symptoms mimic those of other ailments such as rheumatoid arthritis, scleroderma, etc. However, a butterfly-shaped rash, also known as malar rash across the nose and cheek is a highly distinctive feature of lupus. There are other complications that can arise from lupus, such as urinary tract infections, yeast infections, herpes, pregnancy loss, bone tissue death, and others.
Market Dynamics
The high prevalence and incidence of lupus, rapid research and development activities towards development of novel therapeutics for treatment of lupus, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global lupus therapeutic market over the forecast period.
For instance, according to an article published by the Lupus Science and Medicine journal, in April 2021, it is estimated that the incidence and prevalence of Systemic Lupus Erythematosus (SLE) were around 0.3 to 5.1 per 100 000 per year and 6.5 to 85 per 100 000 population, respectively in Europe in 2020.
Key features of the study:
This report provides an in-depth analysis of the global lupus therapeutic market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global lupus therapeutic market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Hikma Pharmaceuticals PLC, Lupus Therapeutics, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., ADMA Biologics, Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global lupus therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lupus therapeutic market
Detailed Segmentation:
Global Lupus Therapeutic Market, By Disease Type:
Systemic Lupus Erythematosus (SLE)
Cutaneous Lupus Erythematosus
Drug-Induced Lupus Erythematosus
Neonatal Lupus
Global Lupus Therapeutic Market, By Treatment Type:
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Biologics
Antimalarial Drugs
Corticosteroids
Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
Global Lupus Therapeutic Market, By Route Of Administration:
Oral
Subcutaneous
Intravenous
Others (Intramuscular, Intradermal, among others)
Global Lupus Therapeutic Market, By End User:
Hospitals & Clinics
Diagnostic Laboratories
Others (Homecare, Specialty Centre, among others)
Global Lupus Therapeutic Market, By Region:
North America
By Disease Type
Systemic Lupus Erythematosus (SLE)
Cutaneous Lupus Erythematosus
Drug-Induced Lupus Erythematosus
Neonatal Lupus
By Treatment Type
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Biologics
Antimalarial Drugs
Corticosteroids
Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
By Route Of Administration
Oral
Subcutaneous
Intravenous
Others (Intramuscular, Intradermal, among others)
By End User
Hospitals & Clinics
Diagnostic Laboratories
Others (Homecare, Specialty Centre, among others)
By Country
U.S.
Canada
Latin America
By Disease Type
Systemic Lupus Erythematosus (SLE)
Cutaneous Lupus Erythematosus
Drug-Induced Lupus Erythematosus
Neonatal Lupus
By Treatment Type
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Biologics
Antimalarial Drugs
Corticosteroids
Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
By Route Of Administration
Oral
Subcutaneous
Intravenous
Others (Intramuscular, Intradermal, among others)
By End User
Hospitals & Clinics
Diagnostic Laboratories
Others (Homecare, Specialty Centre, among others)
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Disease Type
Systemic Lupus Erythematosus (SLE)
Cutaneous Lupus Erythematosus
Drug-Induced Lupus Erythematosus
Neonatal Lupus
By Treatment Type
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Biologics
Antimalarial Drugs
Corticosteroids
Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
By Route Of Administration
Oral
Subcutaneous
Intravenous
Others (Intramuscular, Intradermal, among others)
By End User
Hospitals & Clinics
Diagnostic Laboratories
Others (Homecare, Specialty Centre, among others)
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Disease Type
Systemic Lupus Erythematosus (SLE)
Cutaneous Lupus Erythematosus
Drug-Induced Lupus Erythematosus
Neonatal Lupus
By Treatment Type
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Biologics
Antimalarial Drugs
Corticosteroids
Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
By Route Of Administration
Oral
Subcutaneous
Intravenous
Others (Intramuscular, Intradermal, among others)
By End User
Hospitals & Clinics
Diagnostic Laboratories
Others (Homecare, Specialty Centre, among others)
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Disease Type
Systemic Lupus Erythematosus (SLE)
Cutaneous Lupus Erythematosus
Drug-Induced Lupus Erythematosus
Neonatal Lupus
By Treatment Type
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Biologics
Antimalarial Drugs
Corticosteroids
Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
By Route Of Administration
Oral
Subcutaneous
Intravenous
Others (Intramuscular, Intradermal, among others)
By End User
Hospitals & Clinics
Diagnostic Laboratories
Others (Homecare, Specialty Centre, among others)
By Country
GCC
Israel
Rest of Middle East
Africa
By Disease Type
Systemic Lupus Erythematosus (SLE)
Cutaneous Lupus Erythematosus
Drug-Induced Lupus Erythematosus
Neonatal Lupus
By Treatment Type
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Biologics
Antimalarial Drugs
Corticosteroids
Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
By Route Of Administration
Oral
Subcutaneous
Intravenous
Others (Intramuscular, Intradermal, among others)
By End User
Hospitals & Clinics
Diagnostic Laboratories
Others (Homecare, Specialty Centre, among others)
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
Hikma Pharmaceuticals PLC*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Lupus Therapeutics
Dr. Reddy's Laboratories Ltd.
GlaxoSmithKline plc
Amgen Inc.
Novartis AG
Sanofi
UCB S.A.
ImmuPharma PLC
Bayer AG
Merck & Co., Inc.
Aurinia Pharmaceuticals Inc.
Pfizer Inc.
ADMA Biologics, Inc.
AstraZeneca
F.Hoffmann-La Roche Ltd
Bristol-Myers Squibb Company
Teva Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Boehringer Ingelheim International Gmbh
“*” marked represents similar segmentation in other categories in the respective section.